DelveInsight’s “BK virus (BKV) Infection Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the BK virus (BKV) Infection market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging BK virus (BKV) Infection drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current BK virus (BKV) Infection treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
BK virus (BKV) Infection: An Overview
BK Virus (BKV) Infection also known as polyomavirus is a member of the human polyomavirus family. BKV resides dormant in uroepithelial cells as it is mostly acquired in childhood and is not known to cause tissue damage in immunocompetent individuals. The virus can become reactivated in case of immunodeficiency (e.g., secondary to HIV infection or immunosuppressive medications), and result in cellular damage and organ dysfunction.
The kidney, lung, eye, liver, and brain are sites of BK virus-associated disease, both primary and reactivated. BK virus infection in the kidney manifests as hemorrhagic cystitis, ureteric stenosis, nephritis, etc. Pulmonary diseases that involve the BK virus include pneumonitis and acute nonspecific upper respiratory tract infection.
In transplant recipients, however, BKV reactivation is common. It can lead to distinctive pathological entities in different patient groups such as in renal transplant (RT) recipients, it is associated with nephropathy (BKVN) and ureteral stenosis, and in hematopoietic stem cell transplant (HSCT) recipients with hemorrhagic cystitis (HC).
BK virus (BKV) Infection Market Key Facts
-
As per the study conducted by Bohl et al. titled “BK Virus Nephropathy and Kidney Transplantation,” the pre-transplantation prevalence was from 80-88% for BKV and 54-55% for JCV. The post-transplantation rates of polyomavirus infection were 18-44% for BKV and 30-35% for JCV.
-
As per a study conducted by Sawinski et al. titled “BK virus infection: an update on diagnosis and treatment”, based on DNA sequence variations, BK can be divided into six subtypes or genotypes. Genotype I is the most frequent worldwide (80%) followed by genotype IV (15%). Additionally, approximately one-third of patients with viruria can develop BK viremia (BKV) and, without intervention, could progress to BKVN (rates ranging from 1-10%).
BK virus (BKV) Infection Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging BK virus (BKV) Infection pipeline therapies. It also thoroughly assesses the BK virus (BKV) Infection market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed BK virus (BKV) Infection drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
BK virus (BKV) Infection Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted BK virus (BKV) Infection epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted BK virus (BKV) Infection epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the BK virus (BKV) Infection Epidemiology, Segmented as –
-
Incident/Prevalent Population of BKV Infection (this prevalent patient pool will also comprise a patient pool population derived from renal transplant-associated mainly with Hemorrhagic Cystitis, Ureteric Stenosis, and Nephritis) in the 7MM
-
Diagnosed Cases of BKV Infection in the 7MM
-
Treatable Cases of BKV Infection in the 7MM
BK virus (BKV) Infection Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the BK virus (BKV) Infection market or expected to be launched during the study period. The analysis covers the BK virus (BKV) Infection market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the BK virus (BKV) Infection drugs based on their sale and market share.
The report also covers the BK virus (BKV) Infection pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key BK virus (BKV) Infection companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the BK virus (BKV) Infection Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-market
BK virus (BKV) Infection Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for BK Virus Infections. Currently, AlloVir is leading the therapeutics market with its BK Virus Infections drug candidates in the most advanced stage of clinical development.
BK virus (BKV) Infection Companies Actively Working in the Therapeutics Market Include
-
AlloVir
-
Amplyx Pharmaceuticals
-
SL VAXiGEN
-
Hybridize Therapeutics
And Many Others
Emerging and Marketed BK virus (BKV) Infection Therapies Covered in the Report Include:
-
Viralym-M: AlloVir
-
MAU868: Amplyx Pharmaceuticals
-
MTX-005: Memo Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-marketTable of Content (TOC)
1. Key Insights
2. Executive Summary
3. BK virus (BKV) Infection Competitive Intelligence Analysis
4. BK virus (BKV) Infection Market Overview at a Glance
5. BK virus (BKV) Infection Disease Background and Overview
6. BK virus (BKV) Infection Patient Journey
7. BK virus (BKV) Infection Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. BK virus (BKV) Infection Treatment Algorithm, Current Treatment, and Medical Practices
9. BK virus (BKV) Infection Unmet Needs
10. Key Endpoints of BK virus (BKV) Infection Treatment
11. BK virus (BKV) Infection Marketed Therapies
12. BK virus (BKV) Infection Emerging Drugs and Latest Therapeutic Advances
13. BK virus (BKV) Infection Seven Major Market Analysis
14. Attribute Analysis
15. BK virus (BKV) Infection Market Outlook (In US, EU5, and Japan)
16. BK virus (BKV) Infection Companies Active in the Market
17. BK virus (BKV) Infection Access and Reimbursement Overview
18. KOL Views on the BK virus (BKV) Infection Market
19. BK virus (BKV) Infection Market Drivers
20. BK virus (BKV) Infection Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/bk-virus-bkv-infection-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Dysthymia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Dysthymia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Dysthymia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/